| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Bangers & Mash
|
Budd, Helen
|
|
2010
|
11 |
12 |
p. 1124-1125
2 p.
|
artikel
|
| 2 |
Bevacizumab and breast cancer: the E2100 outlier
|
Fojo, Tito
|
|
2010
|
11 |
12 |
p. 1117-1119
3 p.
|
artikel
|
| 3 |
Biliary cancers, chemotherapy, and cetuximab
|
Malka, David
|
|
2010
|
11 |
12 |
p. 1110-1112
3 p.
|
artikel
|
| 4 |
Biomarkers to predict the clinical efficacy of bevacizumab in cancer
|
Jubb, Adrian M
|
|
2010
|
11 |
12 |
p. 1172-1183
12 p.
|
artikel
|
| 5 |
Breast and ovarian cancer: Y do we forget about dad?
|
McCuaig, Jeanna M
|
|
2010
|
11 |
12 |
p. 1115-1117
3 p.
|
artikel
|
| 6 |
Cancer and cultural differences
|
Burki, Talha
|
|
2010
|
11 |
12 |
p. 1125-1126
2 p.
|
artikel
|
| 7 |
Cetuximab, gemcitabine, and oxaliplatin in patients with unresectable advanced or metastatic biliary tract cancer: a phase 2 study
|
Gruenberger, Birgit
|
|
2010
|
11 |
12 |
p. 1142-1148
7 p.
|
artikel
|
| 8 |
Early landmark studies of smoking and lung cancer
|
Thun, Michael J
|
|
2010
|
11 |
12 |
p. 1200-
1 p.
|
artikel
|
| 9 |
Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial
|
Cuzick, Jack
|
|
2010
|
11 |
12 |
p. 1135-1141
7 p.
|
artikel
|
| 10 |
FDA accelerated approval benefits glioblastoma
|
Cloughesy, Timothy
|
|
2010
|
11 |
12 |
p. 1120-
1 p.
|
artikel
|
| 11 |
HPV-based cervical-cancer screening in China
|
Arbyn, Marc
|
|
2010
|
11 |
12 |
p. 1112-1113
2 p.
|
artikel
|
| 12 |
Lung cancer after treatment for breast cancer
|
Lorigan, Paul
|
|
2010
|
11 |
12 |
p. 1184-1192
9 p.
|
artikel
|
| 13 |
Mammographic surveillance in women younger than 50 years who have a family history of breast cancer: tumour characteristics and projected effect on mortality in the prospective, single-arm, FH01 study
|
|
|
2010
|
11 |
12 |
p. 1127-1134
8 p.
|
artikel
|
| 14 |
Management of small HER2-positive breast cancers
|
Banerjee, Susana
|
|
2010
|
11 |
12 |
p. 1193-1199
7 p.
|
artikel
|
| 15 |
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity
|
Wilson, Wyndham H
|
|
2010
|
11 |
12 |
p. 1149-1159
11 p.
|
artikel
|
| 16 |
52nd ASTRO annual meeting
|
Ceschia, Audrey
|
|
2010
|
11 |
12 |
p. 1123-
1 p.
|
artikel
|
| 17 |
Pancreatic cancer: a neglected killer?
|
The Lancet Oncology,
|
|
2010
|
11 |
12 |
p. 1107-
1 p.
|
artikel
|
| 18 |
Performance of high-risk human papillomavirus DNA testing as a primary screen for cervical cancer: a pooled analysis of individual patient data from 17 population-based studies from China
|
Zhao, Fang-Hui
|
|
2010
|
11 |
12 |
p. 1160-1171
12 p.
|
artikel
|
| 19 |
Rationale for treatment durations of targeted cancer agents
|
Pearson, Sallie-Anne
|
|
2010
|
11 |
12 |
p. 1113-1115
3 p.
|
artikel
|
| 20 |
Screening for breast cancer among women in their 40s
|
Kopans, Daniel B
|
|
2010
|
11 |
12 |
p. 1108-1109
2 p.
|
artikel
|
| 21 |
The Psychological Impact of Breast Cancer
|
Fallowfield, Lesley
|
|
2010
|
11 |
12 |
p. 1124-
1 p.
|
artikel
|
| 22 |
US cancer organisations weigh-in on health-care reform law
|
Nierengarten, Mary Beth
|
|
2010
|
11 |
12 |
p. 1121-1122
2 p.
|
artikel
|
| 23 |
10 years of ATAC: one question answered, many others unresolved
|
Gnant, Michael
|
|
2010
|
11 |
12 |
p. 1109-1110
2 p.
|
artikel
|
Tijdschrift beschrijving